Federico Mingozzi

22.9k total citations · 5 hit papers
122 papers, 10.3k citations indexed

About

Federico Mingozzi is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Federico Mingozzi has authored 122 papers receiving a total of 10.3k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Genetics, 75 papers in Molecular Biology and 39 papers in Oncology. Recurrent topics in Federico Mingozzi's work include Virus-based gene therapy research (91 papers), CAR-T cell therapy research (38 papers) and RNA Interference and Gene Delivery (25 papers). Federico Mingozzi is often cited by papers focused on Virus-based gene therapy research (91 papers), CAR-T cell therapy research (38 papers) and RNA Interference and Gene Delivery (25 papers). Federico Mingozzi collaborates with scholars based in United States, France and Italy. Federico Mingozzi's co-authors include Katherine A. High, Giuseppe Ronzitti, Pasqualina Colella, Klaudia Kuranda, Valder R. Arruda, Helena Costa Verdera, Roland W. Herzog, Daniel J. Hui, Eric Dobrzynski and J. Fraser Wright and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Federico Mingozzi

119 papers receiving 10.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges

2011 728 citations Federico Mingozzi, Katherine A. High profile →
Immune responses to AAV vectors: overcoming barriers to successful gene therapy

2013 676 citations Federico Mingozzi, Katherine A. High Blood profile →
Emerging Issues in AAV-Mediated In Vivo Gene Therapy

2017 617 citations Pasqualina Colella, Giuseppe Ronzitti et al. profile →
CD8+ T-cell responses to adeno-associated virus capsid in humans

2007 573 citations Federico Mingozzi, Daniel J. Hui et al. profile →
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer

2020 446 citations Klaudia Kuranda, Federico Mingozzi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Federico Mingozzi United States	49	7.1k	6.9k	2.6k	1.1k	994	122	10.3k
Roberto Calcedo United States	45	5.2k 0.7×	5.9k 0.9×	1.5k 0.6×	1.1k 1.0×	1.3k 1.3×	85	7.9k
Michel Perricaudet France	64	7.9k 1.1×	6.7k 1.0×	3.1k 1.2×	605 0.5×	1.5k 1.6×	173	13.4k
J. Fraser Wright United States	40	4.4k 0.6×	3.8k 0.6×	3.3k 1.3×	438 0.4×	526 0.5×	89	7.9k
Stefan Kochanek Germany	47	5.7k 0.8×	5.1k 0.7×	1.5k 0.6×	420 0.4×	612 0.6×	150	7.9k
Shangzhen Zhou United States	39	3.8k 0.5×	3.8k 0.5×	1.3k 0.5×	500 0.5×	510 0.5×	69	5.2k
Romain Zufferey Switzerland	22	5.7k 0.8×	4.4k 0.6×	1.2k 0.5×	271 0.2×	744 0.7×	30	8.2k
Ulrike Blömer Germany	20	5.6k 0.8×	4.6k 0.7×	929 0.4×	286 0.3×	946 1.0×	34	8.2k
Peter Bell United States	46	3.9k 0.5×	3.5k 0.5×	746 0.3×	598 0.5×	721 0.7×	100	6.0k
Thierry VandenDriessche Belgium	43	3.9k 0.5×	2.8k 0.4×	1.2k 0.5×	364 0.3×	303 0.3×	124	5.7k
Leonard Meuse United States	30	4.9k 0.7×	4.0k 0.6×	885 0.3×	569 0.5×	612 0.6×	35	6.3k

Countries citing papers authored by Federico Mingozzi

Since Specialization

Citations

This map shows the geographic impact of Federico Mingozzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Mingozzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Mingozzi more than expected).

Fields of papers citing papers by Federico Mingozzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Mingozzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Mingozzi. The network helps show where Federico Mingozzi may publish in the future.

Co-authorship network of co-authors of Federico Mingozzi

This figure shows the co-authorship network connecting the top 25 collaborators of Federico Mingozzi. A scholar is included among the top collaborators of Federico Mingozzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federico Mingozzi. Federico Mingozzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kropf, Elizabeth, et al.. (2024). Complement System Response to Adeno-Associated Virus Vector Gene Therapy. Human Gene Therapy. 35(13-14). 425–438. 15 indexed citations

Vidal, Pierre, Benjamin Bertin, Evelyne Gicquel, et al.. (2023). Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa^−/− mice. Journal of Inherited Metabolic Disease. 47(1). 119–134. 9 indexed citations

Pontoizeau, Clément, Marion Benoist, Pasqualina Colella, et al.. (2023). Successful treatment of severe MSUD in Bckdhb^−/− mice with neonatal AAV gene therapy. Journal of Inherited Metabolic Disease. 47(1). 41–49. 4 indexed citations

Piletska, Elena, P. Véron, Federico Mingozzi, et al.. (2023). Analysis of Adeno-Associated Virus Serotype 8 (AAV8)-antibody complexes using epitope mapping by molecular imprinting leads to the identification of Fab peptides that potentially evade AAV8 neutralisation. Nanomedicine Nanotechnology Biology and Medicine. 52. 102691–102691. 2 indexed citations

Pontoizeau, Clément, Pasqualina Colella, M Girard, et al.. (2022). Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice. Nature Communications. 13(1). 3278–3278. 14 indexed citations

Xiang, Zhiquan, Klaudia Kuranda, William J. Quinn, et al.. (2022). The Effect of Rapamycin and Ibrutinib on Antibody Responses to Adeno-Associated Virus Vector-Mediated Gene Transfer. Human Gene Therapy. 33(11-12). 614–624. 23 indexed citations

Smith, Corinne J., Nikki L. Ross, Kevin Y. Kim, et al.. (2022). Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood. Frontiers in Immunology. 13. 999021–999021. 48 indexed citations

Barbon, Elena, Charlotte Kawecki, Solenne Marmier, et al.. (2021). Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor. Gene Therapy. 30(3-4). 245–254. 25 indexed citations

Zhukouskaya, Volha V., Séverine Charles, Christian Leborgne, et al.. (2021). A novel therapeutic strategy for skeletal disorders: Proof of concept of gene therapy for X-linked hypophosphatemia. Science Advances. 7(44). eabj5018–eabj5018. 5 indexed citations

10.

Hanlon, Killian S., Adrienn Volak, Amine Meliani, et al.. (2020). In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery. Scientific Reports. 10(1). 4544–4544. 25 indexed citations

11.

Barbon, Elena, Jean‐François Ottavi, Charlotte Kawecki, et al.. (2020). Single‐domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. EMBO Molecular Medicine. 12(4). e11298–e11298. 19 indexed citations

12.

Chappert, Pascal, Dominique Urbain, Fanny Collaud, et al.. (2019). Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity. JCI Insight. 4(11). 17 indexed citations

13.

Leborgne, Christian, Sylvie Boutin, Fanny Collaud, et al.. (2018). Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients. Cellular Immunology. 342. 103780–103780. 41 indexed citations

14.

Hudry, Eloïse, Sunil Gandhi, Bence György, et al.. (2016). Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Therapy. 23(4). 380–392. 118 indexed citations

15.

Buchlis, George, et al.. (2012). Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood. 119(13). 3038–3041. 179 indexed citations

16.

Li, Hojun, Nirav Malani, Alexander Schlachterman, et al.. (2010). Assessing the potential for AAV vector genotoxicity in a murine model. Blood. 117(12). 3311–3319. 190 indexed citations

17.

Mingozzi, Federico, J. J. M. Meulenberg, Daniel J. Hui, et al.. (2009). AAV-1–mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood. 114(10). 2077–2086. 227 indexed citations

18.

Ayuso, Eduard, Federico Mingozzi, Joel Montané, et al.. (2009). High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Therapy. 17(4). 503–510. 217 indexed citations

19.

Jiang, Haiyan, Linda B. Couto, Susannah Patarroyo‐White, et al.. (2006). Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood. 108(10). 3321–3328. 276 indexed citations

20.

Castoldi, Elisabetta, et al.. (2001). A highly polymorphic microsatellite in the factor V gene is an informative tool for the study of factor V‐related disorders. British Journal of Haematology. 114(4). 868–870. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact